Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOCUS2: Chemo in Frail/Elderly Colorectal Cancer
NCT00070213Phase 3Completed
- Sponsor
- Medical Research Council
- Start
- Sep 2003
- Primary completion
- Jun 2011
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in metastatic colorectal cancer (mCRC) (4 arms), sponsored by Medical Research Council. Primary endpoints: Progression-Free Survival at 1 year and Quality of Life at 12 weeks. Started Sep 2003; status: completed.
02
Drugs
capecitabineoxaliplatin
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00070213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00070213.